Study Led by Fred Hutch & Emory Investigators Shows SARS-CoV-2 Infected Patients Have Broad, Effective & Possibly Long-Term Immunity

Study Led by Fred Hutch & Emory Investigators Shows SARS-CoV-2 Infected Patients Have Broad, Effective & Possibly Long-Term Immunity

A sophisticated team of researchers operating at Fred Hutchinson Cancer Research Center and Emory University suggest that transcending the COVID-19 pandemic necessitates what they refer to as “long-lived immunity to SARS-CoV-2.” Leading a longitudinal study involving 254 COVID-19 patients over an eight-month period, the study team observed what they referred to as “durable broad-based immune responses” in those mild-to-moderate COVID-19 patients. The investigators remind all that this class of infection represents the vast majority of cases. Although still not peer-reviewed—hence the findings are by no means verified—they do articulate that the prospects look promising as a confluence of factors indicates those infected with SARS-CoV-2 indicate “broad and effective immunity” that could “persist long-term in recovered COVID-19 patients.” The findings, of course, must be reviewed and confirmed, and the authors’ views don’t necessarily reflect those of the academic medical centers that employ them. TrialSite suggests if these findings hold up, they represent powerfully positive information for further study. The study authors will continue tracking the population for two years.

Th...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee